BioCentury
ARTICLE | Clinical News

GLPG0974: Phase IIa started

April 29, 2013 7:00 AM UTC

Galapagos began a double-blind, placebo-controlled, European Phase IIa trial to evaluate 200 mg oral GLPG0974 twice daily for 4 weeks in 45 patients with mild to moderate UC. ...